Patient-reported outcomes (PROs) in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the phase II GEOMETRY mono-1 study

J. Wolf, E. B. Garon, H. J. M. Groen, D. S. -W Tan, Gilloteau, S. Le Mouhaer, C. Cai, A. Chassot-Agostinho, M. Reynolds, D. Odom, R. S. Heist


Originele taal-2English
Pagina's (van-tot)110-110
Aantal pagina's1
TijdschriftOncology Research and Treatment
StatusPublished - sep.-2021

Citeer dit